Recherche
-
Répercussions psychologiques du confinement et de l’épidémie à COVID-19 chez les patients et soignants en hémodialyse en France
(Néphrologie et Thérapeutique, 2021-04-23)Article de revue -
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
(Blood Advances, 2023-10-24)Article de revue -
Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome
(Annales d'Endocrinologie. vol. 83, n° 2, pp. 119-141, 2022-04)Article de revue -
Quantitative susceptibility mapping demonstrates different patterns of iron overload in subtypes of early-onset Alzheimer’s disease
(European Radiology. vol. 33, n° 1, pp. 194-195, 2022-07-26)Article de revue -
PHACTR-1 (Phosphatase and Actin Regulator 1) Deficiency in Either Endothelial or Smooth Muscle Cells Does Not Predispose Mice to Nonatherosclerotic Arteriopathies in 3 Transgenic Mice.
(Arteriosclerosis, Thrombosis, and Vascular Biology. vol. 42, n° 5, pp. 597-609, 2022-05-01)Article de revue -
Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data
(Biostatistics. vol. 25, n° 1, pp. 98-116, 2022-11-18)Article de revue -
Hémopathies lymphoïdes et expositions professionnelles : données du RNV3P 2001–2016
(Archives des Maladies Professionnelles et de L'Environnement. vol. 79, n° 3, pp. 433, 2018-05)Article de revue -
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
(The Lancet. vol. 402, n° 10411, pp. 1434-1448, 2023-10-21)Article de revue -
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial
(The Lancet Infectious Diseases, 2021-03-02)Article de revue -
Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020
(Therapies, 2023-02-15)Article de revue